In December 2008, Cytori presented 12-month preclinical results indicating that ADRCs can promote repair of damaged spinal discs.
In a large animal model, ADRC-treated discs showed a significant increase in disc tissue density and disc-specific extracellular matrix components.
The ‘716 patent covers the therapeutic use of adipose-derived stem and regenerative cells (ADRCs) for promoting repair and regeneration of the spinal disc and formation of bone, cartilage, skeletal muscle, tendon and ligaments.
Cytori president Marc Hedrick said that their technology has shown great potential for disc disease, a spectrum of conditions for which current treatments generally attempt to address the symptoms rather than repair the damaged tissue.
The Celution System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the US.
